Shivakumar

@PeterMacCC | @PeterMacRes

[Shivakumar @ShivakumarIND]

Single‐cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology - Molecular Oncology
https://t.co/rnQzf7ghwf

[Cancer Bioinformatics Australia @VicCanBioinf]

📣Abstract Deadline Extended‼️
Submit your abstracts by our new deadline Tuesday, 22nd April, 9AM AEST.
It's a new race to the finish line for your abstract writing, don't miss your chance to connect with the brilliant cancer bioinformatics community in Australia and overseas.

[Shivakumar @ShivakumarIND]

Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants - European Urology Focus https://t.co/htJzJMgGmK
@PeterMacRes @LukeSelth @ReneaTaylor1

[Shivakumar @ShivakumarIND]

Co‐targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor‐null prostate cancer - Choo - The Journal of Pathology - Wiley Online Library https://t.co/z2kSzXbNVM
@PeterMacRes @MonashPCCC @ReneaTaylor1 @PCR_News @dl_goode @PeterMacCC

[Cancer Bioinformatics Australia @VicCanBioinf]

📢 Abstract submissions are still open for the Cancer Bioinformatics Australia symposium (Deadline: Friday 26th April 2024)!
Share your groundbreaking research and join us in advancing cancer bioinformatics https://t.co/45QHwwIlDU #CancerBioinformatics #Research #Symposium

[Shivakumar @ShivakumarIND]

Defining focal neuroendocrine differentiation as a transcriptionally distinct form of prostate cancer pathology characterized by the expression of androgen receptor
@PeterMacRes
@ReneaTaylor1
@dl_goode https://t.co/KXwU5tsJtv

[Shivakumar @ShivakumarIND]

https://t.co/sct5i9WQGN
@ReneaTaylor1 @dl_goode @SandhuShahneen @PeterMacRes @PMPostdocs

[Shivakumar @ShivakumarIND]

@LOrealAustralia @anna_t_g @PeterMacCC Congratulations @anna_t_g

[Shivakumar @ShivakumarIND]

@ReneaTaylor1 @nhmrc Congratulations @ReneaTaylor1 @PeterMacRes @PeterMacCC

[Renea Taylor @ReneaTaylor1]

Thrilled to be awarded a @nhmrc Synergy Grant with this dynamic and talented team 👇🏻👇🏻👇🏻

[Shivakumar @ShivakumarIND]

I am taking effort to raise funds for Movember for men's mental health, suicide prevention andProstate Cancer 
I'm growing a Mo and would like your support to kick start my fund raising event.
@ReneaTaylor1
@PMPostdocs @PeterMacRes #Movember
URL:
https://t.co/zARVUKnUX3

[Shivakumar @ShivakumarIND]

Share https://t.co/bhsF4cP0jW
@ReneaTaylor1

[Shivakumar @ShivakumarIND]

@ReneaTaylor1 https://t.co/bhsF4cP0jW

[Prostate Cell News @ProstateCell]

Here's a good read!

Researchers at @UniMelb assessed the efficacy of Lewis Y antigen-specific CAR T cells in patient-derived xenograft models of prostate cancer.

Learn more here ⬇️

[Shivakumar @ShivakumarIND]

https://t.co/7DwRxBg5WG

[Renea Taylor @ReneaTaylor1]

3. Pre-treatment with low-dose carboplatin chemotherapy greatly enhances CAR T cell potency, including early and persistent infiltration of activated T cells, resulting in complete tumor regression

[Renea Taylor @ReneaTaylor1]

1. CAR T cells directed to Lewis Y – an onco-foetal glycolipid antigen - was an unexpected target for prostate cancer, with minimal expression in normal tissues, but expressed in 12% of localized, 20% of metastatic and 57% of aggressive prostate tumors

[Renea Taylor @ReneaTaylor1]

@MonashBDI @PeterMacRes 6. We are still searching for the ideal #TME modulating agents that lead to a response to CAR T cell immunotherapy for most prostate tumors. Watch this space!

[Shivakumar @ShivakumarIND]

Can carboplatin treatment facilitate CAR T cell retention and the sustained response to LeY CAR T cells? @PMPostdocs,@PeterMacRes,@MonashPCCC,@ReneaTaylor1 https://t.co/7DwRxBg5WG

[Renea Taylor @ReneaTaylor1]

See our latest publication in @NatureComms on prostate cancer CAR T cell efficacy. Preclinical studies provide proof of concept that modifying the #TME enhances T cell trafficking and activation @MonashBDI @PeterMacRes #prostatecancer #CARTcells https://t.co/Qij2IUvmNr